Overview#
BTIG has downgraded Zimmer Biomet Holdings from a 'Buy' rating to 'Neutral.' This decision is based on the company's weak growth momentum and a lack of catalysts that could boost its stock price in the near term.
Growth Challenges#
The brokerage has removed its previous price target of $112, indicating that it does not foresee significant stock gains in the upcoming quarters. Zimmer Biomet's organic revenue growth has been slowing for the past eight quarters and is projected to remain in the low single-digit range of 1% to 3% through 2026, which aligns with the company's own guidance. BTIG noted that this slowdown is already reflected in the stock's current valuation, which stands at about 10.5 times its expected earnings, lower than its competitors.
Product Launches and Market Reception#
BTIG highlighted that the introduction of new products has not significantly boosted growth. Although Zimmer Biomet launched 22 products in 2025 and plans to introduce eight more in 2026, the market response has been average, failing to generate the expected growth.
Operational Changes and Future Outlook#
The firm also pointed out that the acquisition of Paragon 28 in 2025 has not performed as well as anticipated, leading to reduced expectations for its contribution in 2026. Additionally, Zimmer Biomet is currently transitioning its U.S. salesforce to a direct sales model, a process expected to continue until 2027. While this change may enhance growth in the long run, it could cause short-term disruptions. Furthermore, investments in new technologies, such as autonomous robotics, are not expected to impact the stock until their commercialization, projected for late 2027 or early 2028.
In summary, BTIG believes that the combination of slowing growth, limited product-driven upside, and execution risks will likely restrict Zimmer Biomet's stock performance and valuation in the near future.